Ichimura Hideo, Nawa Takeshi, Yamamoto Yusuke, Shimizu Kei, Kobayashi Keisuke, Kitazawa Shinsuke, Kanbara Hisashige, Odagiri Taihei, Endo Katsuya, Matsunaga Tatsuya, Nakamura Seita, Yagi Satomi, Sato Yukio
Department of Thoracic Surgery, Hitachi General Hospital, Hitachi, Ibaraki 317-0077, Japan.
Department of Thoracic Surgery, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan.
Mol Clin Oncol. 2020 Mar;12(3):278-283. doi: 10.3892/mco.2020.1973. Epub 2020 Jan 10.
We have developed a metallic micro-cavity array filter and an automated detection system for capturing circulating tumor cells (CTCs). In this single institutional pilot study, we assessed the ability of this device to detect CTCs in patients with lung cancer at each stage. Patients diagnosed with lung cancer, undergoing planned surgery for lung cancer, or suspected of having lung cancer were recruited (40 recruited and 2 excluded). Blood samples were obtained from the patients and 3 ml whole blood was applied to the device without any preparation. The captured cells were stained to differentiate the nucleus, and determine cytokeratin and CD45 expression. Subsequently, two operators blinded to clinical information counted the number of CTCs. Sample collection was performed at the time of recruitment, before treatment and ~3 months after initial blood collection. CTC counts at recruitment were 1.4±0.4, 1.8±1.2, 1.3±0.6 and 7.4±5.1 (mean ± SE) in clinical stages I, II, III and IV, respectively. No significant difference was observed among the stages. These data indicated the ability of this device to detect CTCs at early or non-metastatic stages of lung cancer. Further research on a larger scale is needed for a more accurate assessment of the device, and research on the utility of captured cells remains a future challenge.
我们开发了一种用于捕获循环肿瘤细胞(CTC)的金属微腔阵列过滤器和自动检测系统。在这项单中心试点研究中,我们评估了该设备在肺癌各阶段检测CTC的能力。招募了被诊断为肺癌、计划接受肺癌手术或疑似患有肺癌的患者(共招募40例,排除2例)。从患者身上采集血样,将3ml全血未经任何预处理直接应用于该设备。对捕获的细胞进行染色以区分细胞核,并确定细胞角蛋白和CD45的表达。随后,两名对临床信息不知情的操作人员对CTC数量进行计数。样本采集在招募时、治疗前以及首次采血后约3个月进行。临床I、II、III和IV期患者招募时的CTC计数分别为1.4±0.4、1.8±1.2、1.3±0.6和7.4±5.1(平均值±标准误)。各阶段之间未观察到显著差异。这些数据表明该设备能够在肺癌的早期或非转移阶段检测到CTC。需要进行更大规模的进一步研究以更准确地评估该设备,并且对捕获细胞的效用进行研究仍然是未来的一个挑战。